Clinical Trials Logo

Recurrent or Metastatic Breast Cancer clinical trials

View clinical trials related to Recurrent or Metastatic Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03315364 Not yet recruiting - Clinical trials for Recurrent or Metastatic Breast Cancer

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

OPTIMAL
Start date: November 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.

NCT ID: NCT03109249 Not yet recruiting - Clinical trials for Recurrent or Metastatic Breast Cancer

Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

Start date: July 15, 2017
Phase: Phase 1
Study type: Interventional

SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.